Table 2.
Summary of HTA Process Across Non-EU Agencies
| Non-MD | |||
|---|---|---|---|
| MD Specific | Specific | ||
| All Agencies | Agencies | Agencies | |
| (N = 36) | (N = 27) | (N = 9) | |
| Characteristics | N (%)a | N (%)a | N (%)a |
| Process for priority setting | 23 [of 33] (70) | 22 (80) | 3 (38) |
| The unit responsible for priority setting is: | |||
| Internal Unit (e.g., Executive board, scientific committee)b | 18 [of 32] (56) | 16 [of 24] (67) | 2 (25) |
| External Unit (e.g., government, insurance company)b | 20 [of 32] (63) | 15 [of 24] (54) | 7 (88) |
| Technologies are selected/prioritised for assessment by: | |||
| Perceived impact on patient outcomesb | 15 [of 28] (54) | 13 [of 22] (59) | 2 [of 6] (33) |
| Budget impact of the technologyb | 16 [of 28] (57) | 14 [of 22] (64) | 2 [of 6] (33) |
| Prevalence of medical condition | 16 [of 28] (57) | 13 [of 22] (59) | 3 [of 6] (50) |
| Assessment feasibility (e.g., available data, funding)b | 9 [of 28] (32) | 8 [of 22] (36) | 1 [of 6] (17) |
| Any new technologyb | 1 [of 28] (4) | 1 [of 22] (5) | 0 [of 6] (0) |
| Selected new technologyb | 12 [of 28] (43) | 10 [of 22] (45) | 2 [of 6] (33) |
| Technology identified by external stakeholdersb | 19 [of 28] (68) | 15 [of 22] (68) | 4 [of 6] (67) |
| Otherb | 9 [of 28] (32) | 7 [of 22] (32) | 2 [of 6] (33) |
| The assessment work is performed by | |||
| Mainly in-house HTA staff | 25 [of 34] (74) | 19 (72) | 7 (78) |
| Mainly outsourced | 7 [of 34] (21) | 5 (19) | 2 (22) |
| Other | 2 [of 34] (6) | 3 (11) | 0 (0) |
| The organisation | |||
| Commissions reportsb | 13 [of 33] (39) | 11 [of 25] (44) | 2 [of 8] (25) |
| Commissioned to perform reportsb | 25 [of 33] (76) | 18 [of 25] (72) | 7 [of 8] (88) |
| The assessments are based on | |||
| Submissions from external stakeholdersb | 24 [of 32] (75) | 18 [of 25] (72) | 6 [of 7] (86) |
| Internally conducted researchb | 14 [of 32] (44) | 11 [of 25] (44) | 3 [of 7] (43) |
| Products or services produced by the organisation: | |||
| Reports for decision makersb | 32 [of 34] (94) | 23 [of 25] (92) | 9 (100) |
| Research projects with primary datab | 11 [of 34] (35) | 9 [of 25] (36) | 3 (33) |
| Academic and training activitiesb | 19 [of 34] (56) | 12 [of 25] (52) | 6 (67) |
| Clinical practice guidelinesb | 13 [of 34] (38) | 10 [of 25] (40) | 3 (33) |
| Otherb | 7 [of 34] (21) | 6 [of 25] (24) | 1 (11) |
| Types of HTA reports produced | |||
| Full HTA reportb | 24 [of 30] (83) | 20 [of 24] (83) | 5 [of 6] (83) |
| Rapid HTA reportb | 20 [of 30] (67) | 15 [of 24] (63) | 5 [of 6] (83) |
| Otherb | 19 [of 30] (63) | 14 [of 24] (58) | 5 [of 6] (83) |
| Assessment results are made publically available on | |||
| Agency web siteb | 26 [of 35] (74) | 20 [of 27] (74) | 6 [of 8] (75) |
| INAHTA databaseb | 12 [of 35] (34) | 10 [of 27] (37) | 2 [of 8] (25) |
| Otherb | 14 [of 35] (40) | 11 [of 27] (44) | 2 [of 8] (25) |
| Stakeholders (i.e., clinical specialist, patients’ associations, industry) role in the HTA process: | |||
| Trigger HTA processb | 21 [of 34] (62) | 17 [of 26] (65) | 4 [of 8] (50) |
| Involved in the assessment processb | 16 [of 34] (47) | 11 [of 26] (42) | 5 [of 8] (63) |
| Involved in the appraisal processb | 12 [of 34] (35) | 10 [of 26] (38) | 1 [of 8] (25) |
| Involved in reimbursement/pricing decisionsb | 7 [of 34] (21) | 6 [of 26] (23) | 1 [of 8] (13) |
| External review of HTA assessments | 27 [of 33] (82) | 21 [of 21] (81) | 6 [of 7] (86) |
| Have specific measures to ensure transparency of HTA process (e.g. declaration of conflict of interest) | 21 [of 23] (91) | 18 [of 19] (95) | 3 [of 4] (75) |
| Repeat assessments of given technologies in regular intervals | 15 [of 29] (52) | 14 [of 23] (61) | 1 [of 6] 17 |
| The individual or body responsible for technology funding/coverage/policy decision at end of HTA process | |||
| A committee within the same organization | 7 [of 33] (21) | 6 [of 25] (24) | 1 [of 8] (12) |
| A different organisation | 26 [of 33] (78) | 19 [of 25] (76) | 7 [of 8] (88) |
| HTA is mandatory for decision making | 10 [of 33] (31) | 11 [of 25] (44) | 0 [of 8] (0) |
| Decision-making body can deviate from HTA results | 30 [of 31] (97) | 22 [of 23] (96) | 8 [of 8] (100) |
a
All proportions based on the N = 36 (all agencies), N = 27 (MD specific agencies), N = 9 (Non MD specific agencies) unless otherwise indicated.
b
A positive response could be given to more than one item.